Vertex (VRTX), BioMarin (BMRN), Intercept (ICPT), Others Highlighted as Targets at BMO Following PFE/MDVN
Get Alerts MDVN Hot Sheet
Rating Summary:
12 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
Amid Pfizer's (NYSE: PFE) deal to acquire Medivation (NASDAQ: MDVN) for $14 billion, BMO Capital analyst Do Kim sees increased appeal for the remaining mid-cap biotech companies.
Kim issued a list of potential combination candidates in their coverage, using a 3-4x multiple on their peak revenue estimates, including: Vertex Pharma (NASDAQ: VRTX) and Ionis Pharma (NASDAQ: IONS) (covered by Kim group) and Alexion Pharma (NASDAQ: ALXN), AveXis (NASDAQ: AVXS), BioMarin (NASDAQ: BMRN), Intercept Pharma (NASDAQ: ICPT), and Neurocrine Biosciences (NASDAQ: NBIX) (covered by Ian Somaiya).
"We believe these companies could potentially command a higher multiple given the limited number of late-stage clinical and commercial biotechs," he said.
Using the 3-4x peak revenue multiple, the firm's chart shows AveXis (NASDAQ: AVXS), Intercept Pharma (NASDAQ: ICPT), and Neurocrine Biosciences (NASDAQ: NBIX) have the most potential upside in a deal.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- BMO Capital Reiterates Outperform Rating on National Health Investors (NHI)
- Azul (AZUL) Said in Talks With Gol (GOL) Shareholder for Stock-Based Deal - Bloomberg
Create E-mail Alert Related Categories
Analyst Comments, RumorsRelated Entities
BMO Capital, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!